ADRB2 genotype‐guided treatment for childhood asthma: Cost analysis of the PUFFIN and PACT trials
Pediatric Allergy and Immunology · 2025
DOI: 10.1111/pai.70113 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Pediatric Allergy and Immunology, 2025. Verfasst von E M A Slob und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands. Hauptthemen laut MEDLINE: Adrenergic beta-2 Receptor Agonists, Anti-Asthmatic Agents, Asthma, Receptors, Adrenergic, beta-2. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Henry Smith Charity, Action Medical Research, Lung Foundation Netherlands.
Abstract (Originalsprache)
Background
Long‐acting β2‐agonists (LABA) are commonly used to treat asthma. Some children do not respond well to LABA, which may be due to +46G>A−/rs1042713 (Arg16 amino acid) in the ADRB2 gene encoding the β2 receptor. Arg16Gly ADRB2 genotyping to guide treatment step‐up decisions in children with uncontrolled asthma despite inhaled corticosteroids (ICS) has been shown to reduce asthma exacerbations. We investigated whether ADRB2 genotype‐guided treatment is cost‐saving.
Methods
Total semi‐annual healthcare and indirect costs for children with and without exacerbations were calculated using PUFFIN trial data. One hundred and two Dutch and Swiss children were randomised to a genotype‐guided treatment arm (adding LABA [Gly16Gly] or double dose ICS [Arg16Arg/Arg16Gly]) or a control arm, where children were again randomised to LABA or double dose ICS. We used exacerbation rates of the PUFFIN and the PACT trials to calculate asthma‐related healthcare costs per treatment arm, as PACT closely matches the PUFFIN design. The PACT trial randomised 91 children from England and Scotland with uncontrolled asthma to the genotype‐guided treatment arm (LABA [Gly16Gly] or montelukast [Arg16Arg/Arg16Gly]) or the control arm (routine care as per British Thoracic Society guidelines).
Results
Overall mean semi‐annual costs per child were €56.24 lower in the genotype‐guided treatment arm compared to the control arm (€771.07 [range €616.86–€925.28, 23 of 90 children experienced exacerbations] and €827.31 [range €661.85–€992.77, 40 of 103 experienced exacerbations], respectively).
Conclusion
A treatment strategy that includes ADRB2 genotype‐guided treatment is potentially cost‐saving compared to usual care. The decreased healthcare costs associated with a reduction in asthma exacerbations more than offset the incurred genotyping costs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pulmonary Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
- Department of Genetics, University Medical Center Groningen, Groningen, The Netherlands.
- Department of Clinical Pharmacy, Diakonessenhuis, Utrecht, The Netherlands.
- Department of Clinical Pharmacy, Haaglanden Medical Center, The Hague, The Netherlands.
- Department of Public Health, Julius Center Research Program Methodology, University Medical Centre Utrecht, Utrecht, The Netherlands.
- Department of Clinical and Experimental Medicine, Brighton and Sussex Medical School, University of Brighton and University of Sussex, Brighton, UK.
ORCID-Profile: S J H Vijverberg, T Ruffles
Förderung
- Henry Smith Charity
- Action Medical Research
- Lung Foundation Netherlands
Zitieren
APA
Slob, E. M. A., Frederix, G. W. J., Vijverberg, S. J. H., Noij, L. C. E., Ruffles, T., Vasbinder, E. C., Mukhopadhyay, S., van Schaik, R. H. N., Kersten, E. T. G., Pijnenburg, M. W., Koppelman, G. H., Maitland-van der Zee, A. H., & PUFFIN and PACT investigators (2025). ADRB2 genotype‐guided treatment for childhood asthma: Cost analysis of the PUFFIN and PACT trials. Pediatric Allergy and Immunology. https://doi.org/10.1111/pai.70113
Vancouver
Slob EMA, Frederix GWJ, Vijverberg SJH, Noij LCE, Ruffles T, Vasbinder EC, et al. ADRB2 genotype‐guided treatment for childhood asthma: Cost analysis of the PUFFIN and PACT trials. Pediatric Allergy and Immunology. 2025. doi:10.1111/pai.70113
BibTeX
@article{Slob2025,
author = {Slob, E M A and Frederix, G W J and Vijverberg, S J H and Noij, L C E and Ruffles, T and Vasbinder, E C and Mukhopadhyay, S and van Schaik, R H N and Kersten, E T G and Pijnenburg, M W and Koppelman, G H and Maitland-van der Zee, A H and PUFFIN and PACT investigators, PUFFIN and PACT investigators},
title = {ADRB2 genotype‐guided treatment for childhood asthma: Cost analysis of the PUFFIN and PACT trials},
journal = {Pediatric Allergy and Immunology},
year = {2025},
doi = {10.1111/pai.70113}
}
EUVIMED